917 results about "Base J" patented technology

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids or the modification of nucleic acids or proteins, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins e.g., GeoCas9 or variants thereof, and effector domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing or protein modification are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a GeoCas9 and effector domains, are provided.

The present disclosure provides methods for reducing sequencing errors comprising one or any combination of: (i) removing deaminated bases in any nucleic acid molecule throughout a library preparation workflow which includes immobilised splints which bind to the library, the use of a compaction oligonucleotide, optionally with an intervening sequence, formation of closed circular nucleic acids, creating gaps using glycosylase and lyase activities at positions with deaminated bases. The library may be sequenced using pairwise sequencing, e.g. with dark sequencing and / or sequencing using a multivalent labelled probe for the formation of an avidity molecule and soluble primer and polymerase. Method for sequencing concatemers in which the concatermers are contacted with polymerases, soluble primers and a multivalent labelled molecule which forms a complex with the polymerase. Detecting polymerase position and nucleobase bound to the polymerase in the complex. These methods generate higher quality base calls during downstream sequencing workflows.

The invention belongs to the field of gene engineering, and relates to a DNA binding protein based on TraC effect protein, a fusion protein with a cytosine / adenine base editing function, an editing system and nucleic acid molecules or constructs for encoding the DNA binding protein and the fusion protein. The invention also relates to complexes and kits for gene editing comprising the fusion proteins of the invention or the nucleic acid molecules encoding them. The base editing tool disclosed by the invention can realize efficient, accurate and safe base editing in cells of various eukaryotes such as animals and plants. The unique characteristics of the base editing tool enrich the types of existing base editing tools, and the base editing tool has wide application prospects.

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

The invention discloses cytosine deaminase as well as a related biological material and application thereof, and belongs to the technical field of protein. The technical problem to be solved by the invention is to excavate natural cytidine deaminase without sequence preference and improve the base editing efficiency and range. The invention provides a 15th-143rd site protein of which the amino acid sequence is SEQ ID NO.2. The invention also provides a preparation method of the protein. The invention also provides application of the protein and related biological materials thereof in single base editing. According to the application, metagenome big data is utilized, comprehensive and systematic information mining analysis is carried out on novel cytidine deaminase, and a protein L85 which is highly similar to a known DddA protein structure but low in sequence similarity is selected from the novel cytidine deaminase for functional verification. The protein L85 has high catalytic activity as cytidine deaminase, is not limited by target sequence preference, can be widely applied to gene editing in vitro and in cells / tissues, and has good application potential and development value.

The invention provides a molecular marker for detecting pepper light mottle virus L-series resistance genes and application of the molecular marker, and belongs to the technical field of genetic engineering, the molecular marker comprises SNP1 and SNP2, the SNP1 is a base T at the 2574th site of a yellow lantern pepper genome sequence with the NCBI login number of AB523370, and the SNP2 is a base T at the 2832nd site of the yellow lantern pepper genome sequence with the NCBI login number of AB523370; the specific gene sequence is a specific gene sequence of an L-series resistance gene L1c type gene, and the specific gene sequence is a basic group CA at the 2872 site to the 2873 site, a basic group TT at the 2877 site to the 2878 site, a basic group TG at the 2882 site to the 2883 site and a basic group AGA at the 2885 site to the 2887 site of the yellow lantern pepper with the NCBI accession number being AB523374. By utilizing the molecular marker and the specific sequence, the L-series resistance gene types of the yellow lantern pepper and the annual pepper can be rapidly and accurately detected, and the molecular marker can be used for molecular marker-assisted selective breeding.

A deaminase, a fusion protein and the use thereof. The deaminase contains an amino acid sequence having at least 50% sequence identity to any one of SEQ ID NOs: 1-6, 39-164 and 297-312, and the deaminase can deaminize at least one nucleotide in a target polynucleotide. The deaminase can be fused with a nucleic acid-binding polypeptide to obtain various base editors for the sequence-specific base conversion of the target polynucleotide. The performance of the editors can be further improved by means of fusing one or two UGIs, fusing a Gam protein and other strategies.

The invention relates to a single nucleotide polymorphism (SNP) primer of a DSTN gene related to musk ketone content in natural musk and application of the single nucleotide polymorphism (SNP) primer, and belongs to the technical field of biological detection. The invention provides a single nucleotide polymorphism (SNP) primer of a DSTN gene related to the musk ketone content in natural musk, a molecular marker corresponding to the SNP primer is located at a 682371th basic group of a chromosome 23 of a forest musk deer reference genome, the basic group is mutated into A or C, the genotypes are AA and AC, and deoxyribonucleotide sequences of the SNP primer are shown as SEQ ID NO: 1 and SEQ ID NO: 2. According to a breeding target, by eliminating A / A genotype individuals and retaining A / C genotype individuals, the method has the beneficial effects that the relative content character of musk ketone in musk of the forest musk deer is efficiently and quickly identified, and a scientific basis is provided for early breeding of high-quality forest musk deer. The detection method disclosed by the invention is simple and easy to operate, can be carried out in a laboratory, and can also be applied to a genome breeding technology.

The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.

The invention belongs to the technical field of gene editing, and discloses a base editor system and application. According to the invention, a heterologous peptide sequence is inserted into IscB protein, the obtained peptide embedded IscB is fused with deaminase or glycosylase to construct a base editor, and DNA base editing is carried out. According to the base editor system, the size limitation is overcome, and single AAV delivery is achieved; the editing efficiency is obviously improved; the broad-spectrum applicability is realized; the system optimization is more flexible; the method has efficient editing potential in vivo, and the off-target effect is reduced. The invention provides an important new strategy for hyperlipemia treatment and provides a basis for gene therapy of other hereditary diseases.

The invention belongs to the technical field of genes, and discloses a method for efficiently expressing a foreign protein based on an NC048604-1 site in a CHO cell genome. A site for stably expressing protein in the CHO cell genome is located in the 94142000 to 94148000 basic group range of the CHO cell genome NC048604-1, and the nucleotide sequence of the site is as shown in SEQ ID NO: 1. According to the invention, different protein genes are introduced at fixed positions in a CHO cell genome, and stable expression is carried out.

The invention discloses a method for identifying duck palm weight and related molecular marker application thereof, and relates to the technical field of molecular marker-assisted selection, a primer pair is used for amplifying a DNA fragment containing a 63823029th base polymorphic site from the 5'terminal on a fourth chromosome of a duck reference genome IASAASPekinDuckT2T, and the primer pair is used for amplifying a DNA fragment containing the 63823029th base polymorphic site from the 5 '-terminal on the fourth chromosome of the duck reference genome IASAASPekinDuckT2T. The duck reference genome IAASAASPekinDuckT2T is a duck reference genome sequence in a GenBank database, and the duck reference genome sequence is a duck reference genome sequence in the GenBank database; the duck is a Chinese and new white feather meat duck, and the primer pair consists of a DNA (deoxyribonucleic acid) molecule as shown in SEQ ID No.2 and a DNA molecule as shown in SEQ ID No.3. According to the method for identifying the duck foot weight and the application of the related molecular marker, the genotype of the duck can be judged by detecting the genome DNA of the duck, early living screening of the duck foot weight character is achieved, phenotype determination after slaughtering is not needed, the breeding period is remarkably shortened, and the breeding cost is reduced.

The invention relates to the field of gene engineering. In particular, the present invention relates to cytosine deaminases and their use in base editing. More specifically, the invention relates to a method for screening and identifying a deaminase, a base editing system based on a newly identified cytosine deaminase, a method for editing a target sequence in a genome of an organism (such as a plant) by using the base editing system, and a method for screening and identifying the target sequence. As well as genetically modified organisms (e.g., plants) and progeny thereof produced by the method.

The application discloses a SNP molecular marker for identifying the genetic sex of Procambarus clarkii, wherein the nucleotide sequence of the SNP molecular marker is shown as SEQ ID No. 1, and a male individual is shown as GG homozygote at the 43th base position of the nucleotide sequence of the SNP molecular marker, and a female individual is shown as GA heterozygote at the 43th base position of the nucleotide sequence of the SNP marker. The application further discloses primers and kits for detecting the SNP molecular marker, and application of the reagents, primers and kits for detecting the SNP molecular marker in genetic sex identification of the Procambarus clarkii. The SNP marker is closely related to the genetic sex, and can be used for conveniently and quickly identifying the genetic sex of the Procambarus clarkii in the process of family breeding and unisexual breeding of the Procambarus clarkii, and provides a theoretical basis for identification of sex-reversed individuals in the breeding process.

A composition of matter includes an antisense phosphorodiamidate morpholino oligomer (MO) that includes an MO base sequence. The MO base sequence is arranged to bind a corresponding complementary base sequence of messenger RNA (mRNA) transcribed from one or more genes for the beta subunit of human chorionic gonadotropin (hCG-β). An inventive method, for suppressing intracellular synthesis of a beta subunit of human chorionic gonadotropin (hCG-β), includes introducing such an MO into one or more cells.

The invention relates to the technical field of gene editing, in particular to a Cas9 protein mutant and application thereof. According to the present invention, the mutation is introduced at the position far away from the catalytic site to induce the Cas9 protein conformation change so as to obtain the new Cas9 protein mutant, only the Cas9-sgRNA target chain is cut, and the Cas9-sgRNA non-target chain is not cut, such that the new Cas9 protein mutant can be used for constructing the novel base editor, and the high-efficiency base editing can be performed on the mammalian cell genome. The Cas9 protein mutant disclosed by the invention is fused with a mutant TX with DNA binding deletion of 3 '-> 5' exonuclease TREX2, so that the gene editing efficiency of a 3'terminal generated by paired single-nick enzyme cutting can be greatly improved, and the safety of the Cas9 protein mutant is maintained.

The invention relates to the field of DNA nanotechnology, and discloses a DNA origami structure based on functionalized magnetic nanoparticles, a preparation method and application, and the preparation method comprises the following steps: step 1, constructing a DNA origami structure with a cavity through a self-assembly method; the short chains in the DNA origami structure comprise a first short chain, a second short chain and a third short chain; 2, connecting a sulfydryl-functionalized first sequence to the first short chain, and chelating ferrous ions on the first sequence to obtain a sulfydryl-modified DNA origami structure; 3, ferrous ions chelated on the sulfydryl modified DNA origami structure are reduced, and a magnetic functionalized DNA origami structure internally loaded with Fe2O3 particles is obtained; and 4, connecting an antibody to a second short chain in the DNA origami structure through base complementary pairing to obtain the required DNA origami structure. According to the invention, DNA origami is combined with magnetic nanoparticles, efficient and controllable biological magnetic beads are obtained through dual immobilization and antibody modification, and a traditional application scene of DNA origami is broken through.

Provided is an siRNA for inhibiting the gene expression of complement factor B (CFB), or a pharmaceutical composition or conjugate containing the siRNA. The siRNA contains a sense strand and an antisense strand. Each nucleotide in the siRNA is an independent modified or unmodified nucleotide. The sense strand contains a segment of nucleotide sequence I, and the nucleotide sequence I and a nucleotide sequence show in SEQ ID NO: 1 have an equal length and differ by no more than 3 bases. The antisense strand contains a nucleotide sequence II, and the nucleotide sequence II and a nucleotide sequence shown in SEQ ID NO: 2 have an equal length and differ by no more than 3 bases. The siRNA or the pharmaceutical composition or conjugate containing the siRNA can effectively treat and / or prevent diseases related to the mRNA level of the gene expression of the CFB.

The invention relates to a DNA framework structure addressable enzyme ligation method. Specifically, the invention provides a method for accurately regulating and controlling the specific position of an enzyme on a DNA frame structure through an enzyme modification and base complementary pairing principle, and provides a frame nucleic acid with a capture segment and an enzyme with a connecting chain, and the frame nucleic acid with the capture segment and the enzyme with the connecting chain are subjected to base complementary pairing through the connecting chain and the capture segment. Therefore, the enzyme is connected to a predetermined binding site of the framework nucleic acid, and accurate regulation and control of the connection position, number spacing and the like of the enzyme on the framework nucleic acid are realized. The connection method provided by the invention can realize addressable and accurate enzyme position regulation and control on the DNA nano structure, can widen site-specific modification of the enzyme on the DNA frame structure, and has important significance for developing site-specific and high-throughput enzymatic reaction.

Compositions and methods comprising a deaminase for targeted editing of nucleic acids are provided. Also provided are compositions and methods for localizing a heterologous polypeptide to a target DNA molecule, and compositions and methods for targeted editing of nucleic acids. Fusion proteins comprising an RNA-guided nuclease (RGN) and at least one heterologous polypeptide inserted therein are provided, as well as fusion proteins comprising a DNA binding polypeptide and a deaminase. The heterologous polypeptide may be a pilot editing polypeptide or a base editing polypeptide. Compositions also include nucleic acid molecules encoding a deaminase or fusion protein. Vectors and host cells comprising the nucleic acid molecules encoding the deaminase or fusion protein are also provided.

Embodiments are directed to N3-kethoxal reagents and derivatives thereof, and related methods that allow fast and reversible labeling of single-stranded nucleic acids in live cells. By way of example, one aspect is directed to a process for reversible labeling of single-stranded guanine bases in live cells, which results in an effective in vivo method for transcriptome-wide RNA secondary structure mapping and RNA G-quadruplex prediction.

The invention discloses a Cg12n-v4.6 nuclease. The amino acid sequence of the nuclease is as shown in SEQ ID No. 12. The invention also discloses a preparation method of the nuclease. The Cg12n-v4.6 nuclease mutant with increased activity and improved editing efficiency is developed, and the editing efficiency of the Cg12n-v4.6 nuclease mutant is up to 70% or above. Meanwhile, through engineering modification of corresponding sgRNA of Cas12n, the size of the sgRNA skeleton is reduced. An enhanced Cas12n gene editing tool, namely an eCg12n gene editing system, is developed by combining an engineered Cg12n-v4.6 nuclease mutant and a simplified sgRNA skeleton. Meanwhile, by fusing deaminase, a compact cytosine base editor and a compact adenine base editor are constructed, and the cytosine base editor is applied to edit and induce disease genes to generate early termination codons, so that safe knockout of the genes is realized. Compared with an original wild type editing system, the Cg12n-v4.6 nuclease mutant and a compact eCg12n gene editing system derived from the Cg12n-v4.6 nuclease mutant have the advantages that the editing efficiency is improved, the system size is further simplified, and the Cg12n-v4.6 nuclease mutant and the compact eCg12n gene editing system derived from the Cg12n-v4.6 nuclease mutant are more suitable for gene editing application.

The present disclosure generally relates to an evolved cytidine deaminase derived from a cytidine deaminase, and a method of editing DNA using the same. In some aspects, the present disclosure describes directed evolution of a TadA-derived adenosine deaminase (TadA-CD) for cytidine deamination. In some embodiments, the TadA-CD comprises a plurality of mutations as compared to the parent TadA variant. In some embodiments, the TadA-CD is fused to a programmable DNA binding protein. Other aspects of the present disclosure generally relate to a cytosine base editor (CBE) comprising a programmable DNA binding protein and a TadA-CD. In some embodiments, the disclosed cytosine base editor has an improved conversion efficiency and a reduced off-target editing frequency compared to a naturally occurring CBE. Polynucleotides, vectors, and kits for generating and delivering CBE are also provided. Also provided are cells containing such vectors and CBE. In addition, methods of treatment comprising administration of CBE are also provided.

The invention relates to a group of specific amplification primers for mitochondrial genes of procambarus clarkia and application thereof, and belongs to the technical field of molecular biology, and the mitochondrial genes of the procambarus clarkia comprise cytochrome c oxidase I subunit genes and cytochrome b genes. The specific amplification primer of the CO I gene comprises a CO I gene upstream primer and a CO I gene downstream primer, wherein the base sequences of the CO I gene upstream primer and the CO I gene downstream primer are respectively shown as SEQ NO.1 and SEQ NO.2; the specific amplification primer of the Cytb gene comprises a Cytb gene upstream primer and a Cytb gene downstream primer of which the base sequences are respectively as shown in SEQ NO.3 and SEQ NO.4. The invention further discloses a kit for detecting the Cytb gene. According to the amplification method of the mitochondrial gene of the procambarus clarkia, PCR (Polymerase Chain Reaction) amplification is carried out on a DNA (Deoxyribonucleic Acid) template solution of the procambarus clarkia by adopting amplification primers of a mitochondrial COI gene and a Cytb gene of the procambarus clarkia. The procambarus clarkia mitochondrial gene specific amplification primer has high specificity, a single target gene can be stably amplified, the length of the obtained procambarus clarkia mitochondrial COI gene segment reaches about 1000 bp, and the length of the obtained procambarus clarkia mitochondrial Cytb gene segment reaches about 800 bp.

The invention discloses a method for light regulation and control of Cas12a crRNA activity and an application of the Cas12a crRNA activity. Light-caged crRNA is designed according to a target nucleic acid sequence, and is selected from any one or two of the following: (1) complete crRNA: carrying out single-base light-caged modification on nucleotide at a third site or a fourth site at a 5'end of a crRNA fixed region; (2) splitting the crRNA: splitting the crRNA from a stem loop of the fixed region and containing two sequences, the first sequence is nucleotide from the first site to the tenth site at the 5'end of the fixed region of the crRNA, and the nucleotide at the third site or the fourth site at the 5 'end of the fixed region of the crRNA is subjected to single-base light cage modification; the second sequence is the remaining part of the fixed region and the spacer region after the 11th site to the 14th site at the 5'end of the crRNA fixed region are removed. The light-caged crRNA can be used for detecting a nucleic acid sample to be detected by a one-tube method, and the detection sensitivity is high.

The invention discloses a divalent nucleic acid aptamer fluorescence detection method based on an exonuclease I auxiliary target circulation strategy, and belongs to the field of analysis and detection.The divalent nucleic acid aptamer is a repetitive sequence composed of two monovalent nucleic acid aptamers and can form double-stranded DNA through base complementary pairing with complementary strand cDNA of the divalent nucleic acid aptamer, and the divalent nucleic acid aptamer can be used for fluorescence detection of the divalent nucleic acid aptamer. The method comprises the following steps: taking a bivalent nucleic acid aptamer as a template, forming a DNA silver nanocluster (DNA-AgNCs) under the action of silver nitrate and sodium borohydride, and when the target okadaic acid exists, combining the bivalent nucleic acid aptamer with the target, so that cDNA can be replaced from double-stranded DNA by the target. Exonuclease I is added to perform enzyme digestion on the cDNA and the divalent nucleic acid aptamer, so that the fluorescence intensity of the DNA-AgNCs can be rapidly reduced. The content of the okadaic acid can be judged by detecting the change of the fluorescence intensity. The invention provides a simple, convenient, rapid, high-sensitivity and high-specificity detection method for okadaic acid detection based on a divalent nucleic acid aptamer for the first time.

Provided is a reverse prime editing system, which is used for achieving site-specific and precise small-fragment DNA editing upstream of a target site. In the reverse prime editing system, a targeted strand nickase (such as D10A-Cas9) is used to cleave a nick on a targeted strand, thereby enabling precise small-fragment DNA base insertion, deletion and substitution upstream of the target site under the action of a reverse transcriptase.

A method of detecting the level of 5-hydroxymethylcytosines (5-hmc) in a DNA molecule of a cell having a 5-hmc prevalence lower than 0.002% of total DNA bases is provided. The method comprising:(a) attaching a 5-hmc labeling agent to the DNA molecule; and(b) subjecting the DNA molecule to an imaging method suitable for detecting the labeling agent, thereby detecting the level of 5-hmc in the DNA molecule. Also provided is a method of diagnosing cancer in a subject in need thereof, the method comprising:(a) providing a DNA sample of a cell of the subject;(b) detecting the level of 5-hmc in the DNA sample as described herein; wherein a significant decrease in the level of 5-hmc in the DNA sample, as compared to a control DNA sample from a healthy subject is indicative that the subject has cancer.

The invention provides a compound for releasing a urine fluorescent biomarker under induction of mitochondrial DNA mutation as well as a preparation method and application of the compound, and belongs to the technical field of medicines. The compound disclosed by the invention is prepared by the following steps: complementarily pairing a hybrid nucleic acid nano-carrier containing single-stranded DNA (Deoxyribose Nucleic Acid), an annular fluorescent reporter molecule and a Cas12a / crRNA compound through bases of DNA or RNA, and then coating polyethyleneimine and hyaluronic acid. A CRISPR / Cas12a system is selected as a converter of tumor specific mitochondrial DNA mutation information and urine fluorescence signals, a nano delivery system which responds to mtDNA single base mutation and is used for tumor progress monitoring and early metastasis warning is designed and synthesized, and the nano delivery system has a good application prospect in tumor progress monitoring and early metastasis sensitive detection.

The invention discloses a reagent and a method for detecting low-frequency pancreatic cancer KRAS G12D gene mutation based on a Cas12a-Cas13a combined reaction system. The reagent comprises a single-stranded substrate DNA (Deoxyribonucleic Acid), a TRNA (Transcription Ribonucleic Acid), a 12CrRNA, a 13CrRNA, a 12Report and a 13Report; the single-stranded substrate DNA is derived from genome DNA of a to-be-detected sample, after the genome DNA of the to-be-detected sample is extracted, asymmetric PCR is carried out by utilizing a PCR primer pair, namely, the single-stranded substrate DNA is amplified and comprises wild type WT and mutant type MT; the mutant MT is completely matched with a recognition region of 12CrRNA, and a base mismatch exists between the mutant MT and a recognition region of 13CrRNA; a base mismatch exists between the wild type WT and a recognition region of 12CrRNA, and the wild type WT is completely matched with a recognition region of 13CrRNA; the TRNA is a pre-synthesized single-stranded RNA, has a base mismatch with a recognition region of the 12CrRNA, and is completely matched with a recognition region of the 13CrRNA; the 12Reporter is a DNA (Deoxyribose Nucleic Acid) probe of the FAM and BHQ double-standard genes, and the 13Reporter is an RNA (Ribonucleic Acid) probe of the FAM and BHQ double-standard genes. The nucleic acid cleavage activities of Cas12a and Cas13a are jointly utilized to realize multiple signal amplification, so that low-frequency detection of KRAS G12D mutation, which is simple to operate and low in cost, is realized.